Weight-Loss drug may slow uterine tumors before surgery
NCT ID NCT07078838
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 16 times
Summary
This study tests whether tirzepatide, a drug used for diabetes and weight loss, can slow or stop the growth of early-stage endometrial cancer or its precursor (EIN) in women with obesity. Forty participants will either receive tirzepatide or standard care for 4 weeks before their scheduled hysterectomy. Researchers will compare tissue samples to see if the drug reduces cell growth in the uterus.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.